Literature DB >> 12900812

The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis.

Kosaku Nitta1, Takashi Akiba, Keiko Uchida, Akira Kawashima, Wako Yumura, Takashi Kabaya, Hiroshi Nihei.   

Abstract

BACKGROUND: The aortic calcification index (ACI), estimated on abdominal computed tomographic scans, has been associated with the extent of arteriosclerosis in hemodialysis patients. However, the contribution of biochemical markers to the progression of vascular calcification in patients undergoing hemodialysis is not fully understood.
METHODS: We examined the relationship between coronary risk factors; metabolic factors, including serum osteoprotegerin (OPG) concentration; and progression of vascular calcification in 26 dialysis patients.
RESULTS: Mean patient age was 52.6 +/- 8.7 (SD) years, and mean duration of dialysis therapy was 7.7 +/- 5.8 years. ACI was measured twice in each patient, and the mean interscan period was 4.9 +/- 0.3 years. Mean ACI changed from 22.2 +/- 24.2 to 33.9 +/- 28.8 overall, and mean change in ACI (DeltaACI) was 12.0 +/- 9.9. Patients were divided into 2 groups: slow progressors, with DeltaACI of 4.1 +/- 3.2 (n = 13), and rapid progressors, with DeltaACI of 19.8 +/- 7.9 (n = 13). Serum fasting glucose and CRP levels of rapid progressors were high, and their serum albumin and intact parathyroid hormone levels were low. Multiple regression analyses showed that serum OPG levels were independently associated with vascular calcification in the hemodialysis patients studied.
CONCLUSION: Rapid progression of vascular calcification was associated with dose of calcium carbonate prescribed and serum OPG concentration. The clinical significance of these observations remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900812     DOI: 10.1016/s0272-6386(03)00655-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  34 in total

1.  Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.

Authors:  S Gonnelli; A Montagnani; C Caffarelli; A Cadirni; M S Campagna; M B Franci; B Lucani; E Gaggiotti; R Nuti
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

Review 2.  Pathogenesis of vascular calcification in dialysis patients.

Authors:  Markus Ketteler; Ralf Westenfeld; Georg Schlieper; Vincent Brandenburg
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

Review 3.  Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease.

Authors:  János Nemcsik; István Kiss; András Tislér
Journal:  World J Nephrol       Date:  2012-02-06

4.  Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients.

Authors:  A Nakashima; J J Carrero; A R Qureshi; T Hirai; N Takasugi; T Ueno; Y Taniguchi; B Lindholm; N Yorioka
Journal:  Osteoporos Int       Date:  2010-09-02       Impact factor: 4.507

5.  Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease.

Authors:  Michalis Spartalis; Aikaterini Papagianni
Journal:  World J Nephrol       Date:  2016-01-06

6.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein
Journal:  Atherosclerosis       Date:  2007-06-14       Impact factor: 5.162

Review 7.  Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?

Authors:  W Jeffcoate
Journal:  Diabetologia       Date:  2004-08-21       Impact factor: 10.122

8.  The death ligand TRAIL in diabetic nephropathy.

Authors:  Corina Lorz; Alberto Benito-Martín; Anissa Boucherot; Alvaro C Ucero; Maria Pia Rastaldi; Anna Henger; Silvia Armelloni; Beatriz Santamaría; Celine C Berthier; Matthias Kretzler; Jesus Egido; Alberto Ortiz
Journal:  J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 10.121

9.  Elevated serum bone morphogenetic protein 4 in patients with chronic kidney disease and coronary artery disease.

Authors:  Paul F Stahls; Daniel J Lightell; Stephanie C Moss; Corey K Goldman; T Cooper Woods
Journal:  J Cardiovasc Transl Res       Date:  2012-12-04       Impact factor: 4.132

10.  Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis.

Authors:  Fumiko Kojima; Keiko Uchida; Tetsuya Ogawa; Yoshiko Tanaka; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2008-09-13       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.